Exclusive financial advisor to LI-COR Biosciences

KPMG Corporate Finance LLC acted as exclusive financial advisor to LI-COR Biosciences with respect to the sale of phthalocyanine dyes, including IRDye® 700DX, to Rakuten Medical, Inc.

KPMG Corporate Finance LLC (KPMG CF) acted as exclusive financial advisor to LI‑COR Biosciences (LI‑COR) with respect to the sale of phthalocyanine dyes, including IRDye® 700DX, to Rakuten Medical, Inc. (Rakuten Medical).

LI-COR offers research solutions for therapeutics development and robust western blotting. LI‑COR is an industry leader in imaging systems, analysis software, and IRDye Infrared Dye and other reagents for clinical research, optical image‑guided surgery research, quantitative protein analysis, and small animal imaging. LI‑COR is also a leading innovator in systems for measuring global climate change, plant research, and gas analysis. For nearly 50 years, LI-COR has worked to improve the human condition through the design and development of innovative research tools that help scientists solve the challenges that face humanity.

Rakuten Medical is a global biotechnology company developing precision, cell‑targeting investigational therapies on its Illuminox™ platform, which, in preclinical studies, have shown to lead to rapid and selective cell killing and tumor necrosis. Outside of Japan, Illuminox therapies have not yet been approved as safe or effective by any regulatory authority. Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives.

IRDye 700DX is a key component of the mechanism of action for products being developed by Rakuten Medical and is currently being studied in ASP‑1929 clinical trials across multiple oncology indications. The strategic acquisition ensures a consistent and flexible supply chain to further advance development and commercialization of therapies on Rakuten Medical’s Illuminox platform, such as ASP‑1929 and other photoimmunotherapy products.

“This important business transaction reaffirms our commitment at Rakuten Medical to advance our core, Illuminox, platform for treatment of cancer and will ensure the consistent reliable supply of IRDye 700DX,” said Hiroshi Mikitani, chairman and CEO of Rakuten Medical.

Greg Biggs, CEO of LI‑COR, commented, “This agreement with Rakuten Medical supports our current long-standing supply agreement and is a forward-looking strategic and operational win for both companies. We are pleased that the innovative technology we developed will potentially produce meaningful benefit to the medical community, patients, and families battling cancer.”

Bill Biggs, founder and chairman of LI-COR, further added, “I want to express my hardy thank you to the entire team at KPMG CF that helped bring about a great deal with Rakuten Medical. We could not be happier.”

Financial details of this transaction are confidential.

Global coverage. Industry knowledge. Mid-market focus.

The global Corporate Finance practice of KPMG International’s network of independent member firms was ranked number 1 as the top M&A mid-market adviser globally by Refinitiv, based on number of completed transactions, for the past 20 years.

KPMG Corporate Finance LLC

KPMG Corporate Finance LLC provides a broad range of investment banking and advisory services to its domestic and international clients. Our professionals have the experience and depth of knowledge to advise clients on global mergers and acquisitions, sales and divestitures, buyouts, financings, debt restructurings, equity recapitalizations, infrastructure project finance, capital advisory, portfolio solutions, fairness opinions, and other advisory needs.

Trust KPMG Corporate Finance LLC with your next transaction.


Jason Moran

Jason Moran

Managing Director, KPMG Corporate Finance LLC

+1 415-963-7353

Corporate finance services, including Financing, Debt Advisory, and Valuation Services, are not performed by all KPMG member firms and are not offered by member firms in certain jurisdictions due to legal or regulatory constraints. The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act upon such information without appropriate professional advice after a thorough examination of the particular situation. 
The information contained in this communication may not be representative of the experience of other clients and does not constitute a recommendation, offer, or solicitation to buy, sell or hold any security of any issuer. Past performance does not guarantee future results.
©2021 KPMG Corporate Finance LLC, a Delaware limited liability company. Member FINRA/SIPC. KPMG Corporate Finance LLC is a subsidiary of KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. The KPMG name and logo are registered trademarks or trademarks of KPMG International.